Dr. Beer on Characterization of Immune-Related Adverse Events of Ipilimumab Versus Placebo in mCRPC
Автор: Targeted Oncology
Загружено: Apr 29, 2014
Просмотров: 64 views
Tomasz Beer, MD, FACP, professor of medicine, deputy director of the Knight Cancer Institute, Oregon Health and Science University, characterizes the immune-related adverse events associated with ipilimumab in a phase III metastatic castration-resistant prostate cancer trial.
For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/

Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке: